Fontaine S J, McCulloch E, Eckersall P D, Haining H, Patterson Kane J C, Morris J S
School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
ReactivLab Ltd, University of Glasgow, Glasgow, UK.
Vet Comp Oncol. 2017 Dec;15(4):1513-1526. doi: 10.1111/vco.12296. Epub 2017 Feb 2.
The modified Glasgow Prognostic Score (mGPS) assigns a numerical value (0-2) from pre-treatment serum concentrations of C-reactive protein (CRP) and albumin to predict patient outcome. CRP and albumin were evaluated in 77 untreated dogs with lymphoma to determine the relationship of mGPS to clinicopathological parameters and whether it could predict progression-free (PFS) and overall survival (OS) in treated dogs. mGPS distribution was significantly associated with clinical stage, substage b, weight loss, gastrointestinal disturbances and lethargy at presentation. On univariate analysis, mGPS was significantly associated with OS and PFS, with shorter median survival times for mGPS 2 compared to mGPS 0 and 1 combined. Hypoalbuminaemia significantly reduced OS and PFS, however increased CRP had no effect. Only clinical stage was significantly associated with OS and PFS on both univariate and multivariate analysis. mGPS has potential prognostic value for canine lymphoma , but further studies are needed.
改良格拉斯哥预后评分（mGPS）根据治疗前血清C反应蛋白（CRP）和白蛋白浓度赋予一个数值（0 - 2），以预测患者预后。对77只未经治疗的淋巴瘤犬进行了CRP和白蛋白评估，以确定mGPS与临床病理参数的关系，以及它是否能够预测治疗犬的无进展生存期（PFS）和总生存期（OS）。mGPS分布与临床分期、亚分期b、体重减轻、胃肠道紊乱以及就诊时的嗜睡显著相关。单因素分析显示，mGPS与OS和PFS显著相关，与mGPS 0和1合并组相比，mGPS 2的中位生存时间更短。低白蛋白血症显著降低了OS和PFS，然而CRP升高则没有影响。单因素和多因素分析均显示，只有临床分期与OS和PFS显著相关。mGPS对犬淋巴瘤具有潜在的预后价值，但仍需进一步研究。
